Welcome to our dedicated page for Aprea Therapeutics news (Ticker: APRE), a resource for investors and traders seeking the latest updates and insights on Aprea Therapeutics stock.
Aprea Therapeutics, Inc. reports developments as a clinical-stage precision medicine oncology company developing targeted therapies for patients with biomarker-defined cancers. Its updates center on small-molecule programs designed to exploit cancer-specific genetic vulnerabilities, including APR-1051, an oral WEE1 kinase inhibitor, and ATRN-119, a small-molecule ATR inhibitor, for solid tumor indications.
Recurring news themes include clinical activity from the ACESOT-1051 study of APR-1051, oncology conference presentations, pipeline and corporate updates, financial results, and financing activity supporting research and development. Company communications also describe biomarker-guided development, safety and tolerability observations, and capital actions tied to its clinical-stage oncology strategy.
Aprea Therapeutics (Nasdaq: APRE) expanded its global patent estate in 2025 for its DNA damage response (DDR) oncology programs, with new patents granted in Australia and Japan and multiple pending applications worldwide.
Key points: lead WEE1 inhibitor APR-1051 is in Phase 1 (ACESOT-1051) and ATR inhibitor ATRN-119 is in clinical testing (ABOYA-119); core patents may provide protection into 2045 if pending applications issue.
Aprea Therapeutics (Nasdaq: APRE) announced on February 4, 2026 the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor following early clinical proof-of-concept for its WEE1 inhibitor APR-1051.
The company says Dr. Kennedy brings 20+ years of oncology clinical development, regulatory experience, and senior leadership to help advance dose escalation, refine patient selection, and support the DNA damage response (DDR) program toward key clinical and regulatory milestones.
Aprea Therapeutics (NASDAQ: APRE) reported early clinical proof-of-concept for single-agent WEE1 inhibitor APR-1051 in the Phase 1 ACESOT-1051 dose-escalation trial on Jan 29, 2026. An unconfirmed partial response was observed at the 150 mg dose with ~50% target lesion reduction and CA-125 fall from 732 to 70 U/mL.
Multiple patients showed stable disease and tumor reductions across 70 mg, 100 mg and 150 mg cohorts; 220 mg cohort is enrolling and dose escalation will continue to define the RP2D.
Aprea Therapeutics (Nasdaq: APRE) announced a private placement to sell 6,288,857 shares (or pre-funded warrants) plus warrants to purchase an additional 6,288,857 shares, with a combined effective offering price of $0.89 per unit, generating estimated gross proceeds of $5.6 million.
Warrants have a $0.765 exercise price, are exercisable immediately, and expire two years after the resale registration statement effectiveness; proceeds will fund R&D and to backfill patients in the ACESOT-1 APR-1051 study. Maxim Group is sole placement agent; close expected on or about Jan 30, 2026.
Aprea Therapeutics (Nasdaq: APRE) issued a shareholder letter dated Dec 18, 2025 summarizing 2025 clinical progress and 2026 plans. Key points: lead WEE1 inhibitor APR-1051 is in the ACESOT-1051 dose-escalation study with enrollment in the 220 mg cohort; through 150 mg there have been no dose-limiting toxicities, the longest on-treatment duration is 222 days, and the best observed tumor reduction is 15%. The protocol was amended to add more HPV-positive patients; further safety and efficacy data are expected in Q1 2026 and dose escalation completion is planned in 2026.
The ATR inhibitor ATRN-119 reached a recommended Phase 2 dose for once-daily dosing; the company paused monotherapy enrollment to preserve cash while evaluating combination strategies. Aprea completed a $3.1 million gross private placement and says cash runway extends into Q1 2027.
Aprea Therapeutics (Nasdaq: APRE) announced a private placement to sell 2,623,023 shares (or pre-funded warrants) plus warrants to purchase up to 2,623,023 shares, priced at-the-market under Nasdaq rules.
The combined effective offering price per share (or pre-funded warrant) with accompanying warrant is $1.165, producing estimated gross proceeds of approximately $3.1 million before placement agent fees and expenses. Warrants carry a $1.04 exercise price, are exercisable immediately, and expire on the five-year anniversary tied to registration/resale eligibility.
The company said net proceeds are intended for general corporate purposes and R&D and are expected to extend cash runway into Q1 2027. The Offering is expected to close on or about December 10, 2025, with Maxim Group as sole placement agent.
Aprea Therapeutics (Nasdaq: APRE) reported Q3 2025 results and a clinical update on Nov 12, 2025. The company has $13.7M cash and says runway extends into the fourth quarter of 2026. Clinical highlights: APR-1051 (WEE1 inhibitor) showed 3 of 4 patients with stable disease at 100 mg QD in ACESOT-1051; dose escalation advanced to 150 mg QD. ATRN-119 (ATR inhibitor) identified a RP2D of 1,100 mg QD in ABOYA-119 and enrollment is being paused to evaluate combination strategies. Financials: Q3 operating loss was $3.1M and net loss was $3.0M ($0.47 per share).
Aprea (Nasdaq: APRE) reported preliminary Phase 1 ACESOT-1051 data through Sept 17, 2025 and a data cutoff of Oct 19, 2025 showing early signs of activity for WEE1 inhibitor APR-1051.
At the 100 mg dose (Dose Level 6), 3 of 4 patients achieved stable disease by RECIST v1.1, including tumors with FBXW7, CCNE1, KRAS G12V and TP53 alterations. No dose-limiting toxicities were reported and dose escalation has advanced to 150 mg (Dose Level 7). Individual patients remain on treatment up to 145 days. A poster is being presented at the AACR-NCI-EORTC conference.
Aprea Therapeutics (Nasdaq: APRE) identified a recommended Phase 2 dose (RP2D) of 1,100 mg once daily for ATRN-119 in the monotherapy arm of the ABOYA-119 Phase 1/2a study in advanced solid tumors.
The company is pausing further enrollment in once-daily and twice-daily monotherapy arms to prioritize combination strategies (radiation, antibody-drug conjugates, immune checkpoint inhibitors) based on preclinical synergy; current patients will continue therapy without interruption.
Aprea will present updated ABOYA-119 data on Oct 24, 2025 at the AACR-NCI-EORTC conference. Separately, lead WEE1 program APR-1051 is actively enrolling; patients have received doses up to 150 mg once daily with early disease-stabilization signals. Clinical data for APR-1051 are expected to be reported later this month.
Aprea Therapeutics (Nasdaq: APRE) announced two poster presentations at the EORTC‑NCI‑AACR International Conference on Molecular Targets and Cancer Therapeutics in Boston, Oct 22–26, 2025.
Two abstracts — updated phase 1 data for APR-1051 (WEE1 inhibitor) and updated phase 1/2a data for ATRN-119 (ATR inhibitor) — will be shown as posters on Oct 24, 2025, 12:30–16:00 ET in Exhibit Hall D. Posters will be posted on Aprea’s Investor Resources page the day of presentation.